The first report dates to 2001, when Lorenzi et al. reported the case of a patient with SSc-associated severe GAVE who was treated with intravenous (IV) methylprednisolone and cyclophosphamide for progressive ILD and diffuse skin disease; together with improvement in ILD and cutaneous involvement, his Hb levels stabilised and subsequent OGDs documented resolution of GAVE. This evidence concerns the gene GSTM1 and gastric antral vascular ectasia.